CSL (OTCMKTS:CSLLY) Stock Price Up 8.6% - Here's What Happened

Key Points

• CSL Limited ADR (CSLLY) rose 8.6% on Friday, trading as high as $26.61 and last at $26.03 on just 65,070 shares — roughly an 80% drop from its average daily volume of 329,145.
• Analysts are mixed: Royal Bank of Canada downgraded CSL from "moderate buy" to "hold" while Zacks moved it from "strong sell" to "hold", leaving a consensus rating of "Moderate Buy" (one Strong Buy, two Holds).
• CSL is a Melbourne-based global biotechnology company (CSL Behring, Seqirus, CSL Plasma) focused on plasma-derived therapeutics and vaccines, with a debt-to-equity of 0.50 and liquidity ratios of current 2.46 and quick 1.12.

CSL Limited Sponsored ADR (OTCMKTS:CSLLY - Get Free Report) traded up 8.6% on Friday . The stock traded as high as $26.61 and last traded at $26.03. 65,070 shares traded hands during trading, a decline of 80% from the average session volume of 329,145 shares. The stock had previously closed at $23.96.

Analysts Set New Price Targets

Several research analysts have recently issued reports on CSLLY shares. Royal Bank Of Canada cut shares of CSL from a "moderate buy" rating to a "hold" rating in a report on Wednesday, February 11th. Zacks Research raised CSL from a "strong sell" rating to a "hold" rating in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy".

CSL Stock Performance

The company has a 50-day moving average of $49.02 and a 200-day moving average of $58.03. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12.

CSL Company Profile

CSL Limited OTCMKTS: CSLLY is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL's acquisition of Novartis' influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company's product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.